Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

Figure 7

Effect of the treatments on Cu/ZnSOD and MnSOD activity, evaluated in ischemic left ventricle area from control- (CT-) and diabetic- (DB-) rats subjected to sham- (SH-) or ischemia/reperfusion- (I/R-) myocardial infarction and treated subchronically (14 d) with either vehicle, fenofibrate (Feno, 100 mg/kg), metformin (Metfor, 100 or 300 mg/kg), or Feno (50 mg/kg) + Metfor (50 mg/kg). (a) Cu/ZnSOD and (b) MnSOD activity (–6 rats/group). versus CTSH-Vehicle, versus DBSH-Vehicle, versus CTI/R-Vehicle, and versus DBI/R-Vehicle two-way ANOVA followed by Duncan’s post hoc test. Data are presented as means ± SEM.

(a)

(b)